Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BAG2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BAG2 Full-Length & BAG-Domain Truncation Mutant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by SEC-MALS. |
View BAG2 Products |
| Gene Delivery | BAG2 Promise-ORF / Lentivirus Full-length ORF for stable cell-line construction (HEK293 expressed). |
View BAG2 Products |
| Benchmark Ab | Anti-BAG2 (Research Control) Recombinant rabbit mAb positive control for Western, ICC, and ELISA. |
View BAG2 Products |
| Validator | BAG2 siRNA Set For knockdown verification and target-engagement specificity controls. |
View BAG2 Products |
| Related Target A: HSPA8 | HSPA8 (HSC70) Recombinant Protein Direct PPI partner; essential for BAG2 SPR/BLI and AlphaScreen assays. |
View HSPA8 Products |
| Related Target B: BAG3 | BAG3 Recombinant Protein Closest paralog for BAG-family selectivity counter-screening. |
View BAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BAG-family selectivity (BAG1/BAG3/BAG6 off-target) | Homolog panel proteins (BAG1, BAG3, BAG4, BAG5) strictly sequence-verified by mass spec; >95% purity. |
| Cross-species cyno/mouse evaluation | Human / Mouse / Cyno ortholog proteins available with matched endotoxin specs. |
| PROTAC / Small Molecule Binding Validation | High Purity (>95%) recombinant BAG2 optimized for SPR and BLI assays; Endotoxin Controlled. |
| Lack of intracellular target-engagement controls | BAG2 full-length lentivirus & siRNA set for cellular thermal shift and knockdown rescue assays. |
| False positives in PPI assays | BAG-domain deletion mutant included as negative control in SPR/BLI. |
Live BAG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BAG2 therapeutics is intensifying as researchers uncover its dual role in oncology and neurodegenerative diseases. As an intracellular co-chaperone that interacts with HSP70/HSC70, BAG2 regulates protein homeostasis. In oncology, its overexpression is linked to mutant p53 stabilization and tumor aggressiveness. Conversely, in tauopathies like Alzheimer's disease, BAG2 promotes the clearance of misfolded tau aggregates. Major players are shifting focus from broad HSP90 inhibition to precise co-chaperone modulation. As first-generation small-molecule BAG2-HSP70 disruptors enter lead optimization, the next wave of R&D is targeting CNS-penetrant modalities for tauopathies and combination therapies with proteasome inhibitors in solid tumors.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Disruptor) | Academic consortia & emerging biotechs | Solid Tumors, Tauopathies | SPR / BLI with HSPA8; Selectivity panel vs BAG3/BAG1 |
| PROTAC / Molecular Glue | TPD-focused discovery platforms | Refractory Oncology | Cell-based ternary complex (need BAG2 lentivirus stable line) |
| Gene Therapy / RNAi | CNS-focused biotechs | Alzheimer's Disease, Parkinson's | Expression Validation (need strictly Sequence Verified Lentivirus) |
| Peptide / Miniprotein | Early-stage discovery programs | Neurodegeneration | Ortholog cross-reactivity (Human / Cyno / Mouse BAG2) |